BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors

B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive hematological disease that kills ~50% of adult patients. With the exception of some BCR-ABL1(+) patients who benefit from tyrosine kinase inhibitors, there are no effective targeted therapies for adult B-ALL patients and chemotherapy remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Korfi, K, Smith, M, Swan, J, Somervaille, T C P, Dhomen, N, Marais, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855656/
https://www.ncbi.nlm.nih.gov/pubmed/27054332
http://dx.doi.org/10.1038/cddis.2016.70

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855656/
https://www.ncbi.nlm.nih.gov/pubmed/27054332
http://dx.doi.org/10.1038/cddis.2016.70

Ejemplares similares